175 related articles for article (PubMed ID: 21059859)
21. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
22. [ALK, a key gene in the pathogenesis of neuroblastoma].
Janoueix-Lerosey I; Delattre O
Med Sci (Paris); 2009 Apr; 25(4):330-2. PubMed ID: 19409178
[No Abstract] [Full Text] [Related]
23. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
24. Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association.
Tomiyama A; Uekita T; Kamata R; Sasaki K; Takita J; Ohira M; Nakagawara A; Kitanaka C; Mori K; Yamaguchi H; Sakai R
Cancer Res; 2014 Jul; 74(14):3790-801. PubMed ID: 24830726
[TBL] [Abstract][Full Text] [Related]
25. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma.
Cazes A; Louis-Brennetot C; Mazot P; Dingli F; Lombard B; Boeva V; Daveau R; Cappo J; Combaret V; Schleiermacher G; Jouannet S; Ferrand S; Pierron G; Barillot E; Loew D; Vigny M; Delattre O; Janoueix-Lerosey I
Cancer Res; 2013 Jan; 73(1):195-204. PubMed ID: 23139213
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathogenesis of peripheral neuroblastic tumors.
Janoueix-Lerosey I; Schleiermacher G; Delattre O
Oncogene; 2010 Mar; 29(11):1566-79. PubMed ID: 20101209
[TBL] [Abstract][Full Text] [Related]
27. Genetics and genomics of neuroblastoma.
Capasso M; Diskin SJ
Cancer Treat Res; 2010; 155():65-84. PubMed ID: 20517688
[TBL] [Abstract][Full Text] [Related]
28. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
29. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma.
Deyell RJ; Attiyeh EF
Cancer Genet; 2011 Mar; 204(3):113-21. PubMed ID: 21504710
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the expression of the ALK receptor tyrosine kinase in mice.
Vernersson E; Khoo NK; Henriksson ML; Roos G; Palmer RH; Hallberg B
Gene Expr Patterns; 2006 Jun; 6(5):448-61. PubMed ID: 16458083
[TBL] [Abstract][Full Text] [Related]
31. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.
Carén H; Abel F; Kogner P; Martinsson T
Biochem J; 2008 Dec; 416(2):153-9. PubMed ID: 18990089
[TBL] [Abstract][Full Text] [Related]
32. Germline gain-of-function mutations of ALK disrupt central nervous system development.
de Pontual L; Kettaneh D; Gordon CT; Oufadem M; Boddaert N; Lees M; Balu L; Lachassinne E; Petros A; Mollet J; Wilson LC; Munnich A; Brugière L; Delattre O; Vekemans M; Etchevers H; Lyonnet S; Janoueix-Lerosey I; Amiel J
Hum Mutat; 2011 Mar; 32(3):272-6. PubMed ID: 21972109
[TBL] [Abstract][Full Text] [Related]
33. The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo.
Schönherr C; Ruuth K; Eriksson T; Yamazaki Y; Ottmann C; Combaret V; Vigny M; Kamaraj S; Palmer RH; Hallberg B
Transl Oncol; 2011 Aug; 4(4):258-65. PubMed ID: 21804922
[TBL] [Abstract][Full Text] [Related]
34. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
[TBL] [Abstract][Full Text] [Related]
35. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Choi YL; Soda M; Yamashita Y; Ueno T; Takashima J; Nakajima T; Yatabe Y; Takeuchi K; Hamada T; Haruta H; Ishikawa Y; Kimura H; Mitsudomi T; Tanio Y; Mano H;
N Engl J Med; 2010 Oct; 363(18):1734-9. PubMed ID: 20979473
[TBL] [Abstract][Full Text] [Related]
36. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.
Mourali J; Bénard A; Lourenço FC; Monnet C; Greenland C; Moog-Lutz C; Racaud-Sultan C; Gonzalez-Dunia D; Vigny M; Mehlen P; Delsol G; Allouche M
Mol Cell Biol; 2006 Aug; 26(16):6209-22. PubMed ID: 16880530
[TBL] [Abstract][Full Text] [Related]
38. Identification of ALK as a major familial neuroblastoma predisposition gene.
Mossé YP; Laudenslager M; Longo L; Cole KA; Wood A; Attiyeh EF; Laquaglia MJ; Sennett R; Lynch JE; Perri P; Laureys G; Speleman F; Kim C; Hou C; Hakonarson H; Torkamani A; Schork NJ; Brodeur GM; Tonini GP; Rappaport E; Devoto M; Maris JM
Nature; 2008 Oct; 455(7215):930-5. PubMed ID: 18724359
[TBL] [Abstract][Full Text] [Related]
39. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
[TBL] [Abstract][Full Text] [Related]
40. Role of HER2/neu in tumor progression and therapy.
Ménard S; Casalini P; Campiglio M; Pupa SM; Tagliabue E
Cell Mol Life Sci; 2004 Dec; 61(23):2965-78. PubMed ID: 15583858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
